Trial · NCT01647828
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 2.5 mg/kg + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 5 mg/kg + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 5 mg/kg + Nab-P + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 7.5 mg/kg + Nab-P + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 10 mg/kg + Nab-P + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 12.5 mg/kg + Nab-P + Gem | 0 | Participants | ||
| Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) | P1B: OMP-59R5 15 mg/kg + Nab-P + Gem | 1 | Participants | ||
| Phase 2: Overall Survival (ITT Population) | P2: Placebo + Nab-P + Gem | Number of subjects who died | 60 | participants | |
| Phase 2: Overall Survival (ITT Population) | P2: OMP-59R5 15 mg/kg + Nab-P + Gem | Number of subjects who died | 71 | participants | |
| Phase 2: Overall Survival (ITT Population) | P2: Placebo + Nab-P + Gem | Number of subjects who did not die | 28 | participants | |
| Phase 2: Overall Survival (ITT Population) | P2: OMP-59R5 15 mg/kg + Nab-P + Gem | Number of subjects who did not die | 18 | participants | |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: Placebo + Nab-P + Gem | Notch 3 ≥ 75th percentile | 187.5 | 95% Confidence Interval 95.0 to NA | Days |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: OMP-59R5 15 mg/kg + Nab-P + Gem | Notch 3 ≥ 75th percentile | 228.0 | 95% Confidence Interval 101.0 to 453.0 | Days |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: Placebo + Nab-P + Gem | Notch 3 ≥ 50th percentile | 220.5 | 95% Confidence Interval 135.0 to 329.0 | Days |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: OMP-59R5 15 mg/kg + Nab-P + Gem | Notch 3 ≥ 50th percentile | 151.0 | 95% Confidence Interval 101.0 to 258.0 | Days |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: Placebo + Nab-P + Gem | Notch 3 ≥ 25th percentile | 206.0 | 95% Confidence Interval 146.0 to 312.0 | Days |
| Phase 2: Median OS by Notch 3 Percentile (ITT Population) | P2: OMP-59R5 15 mg/kg + Nab-P + Gem | Notch 3 ≥ 25th percentile | 165.0 | 95% Confidence Interval 123.0 to 252.0 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01647828/results